Diorasis Therapeutics is a preclinical-stage company focused on developing gene therapy for glaucoma. Their disease-modifying, gene-agnostic treatment involves a single intracameral injection producing a modified plasminogen activator. This therapy aims to normalize trabecular meshwork outflow and intraocular pressure, potentially significantly